Eli Lilly & Co earnings were $26.7B for the trailing 12 months ending Jun 30, 2026, with 94.4% growth year over year. The latest LLY earnings report on Jun 30, 2026 announced Q2 2026 earnings of $7.1B, down 4.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LLY reported annual earnings of $20.6B, with 94.9% growth.
LLY past earnings growth
How has LLY's earnings growth performed historically?
On LLY's earnings call on Aug 5, 2026, Eli Lilly & Co (NYSE: LLY) reported Q2 2026 earnings per share (EPS) of $7.95, up 26.19% year over year. Total LLY earnings for the quarter were $7.10 billion. In the same quarter last year, Eli Lilly & Co's earnings per share (EPS) was $6.30.
As of the last Eli Lilly & Co earnings report, Eli Lilly & Co is currently profitable. Eli Lilly & Co's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $26.71 billion, a 93.56% increase year over year.
What was LLY's earnings growth in the past year?
As of Eli Lilly & Co's earnings date in Aug 5, 2026, Eli Lilly & Co's earnings has grown 94.4% year over year. This is 64.65 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 29.75%. LLY earnings in the past year totalled $26.71 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.